Vol. 41 | No. 1 | January-June 2013Back

Open Access

Baseline High-density Lipoprotein Cholesterol as a Predictor of Major Adverse Cardiac Events After Elective Percutaneous Coronary Stenting Among Filipinos

Jun Maximo F. Lasco II, Gilbert C. Vilela
Jun 2013 DOI 10.69944/pjc.ca68407cf8

More Info

Jun Maximo F. Lasco II, MD, Gilbert C. Vilela, MD 

References
  1. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007;297:499-508. 
  2. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:S11–S20. 
  3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741. 
  4. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15. 
  5. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol level. JAMA 1986;256:2835-2838. 
  6. Roswitha WM, Brewer BH, Xue Z, Lowell SF, Pichard AD et al. Impact of low high density lipoproteins on in-hospital events and one– year clinical outcomes in patients with non-ST elevation myocardial infarction acute coronary syndrome treated with drug eluting stent implantation. Am J Cardiol 2006;98:711-717. 
  7. Kini AS, Muntner P, Moreno PR, Mann D, Krishnan P, Kin MC, et al. Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70mg/dl. Am J Cardiol 2009;103:350-354. 
  8. Ghazzal ZB, Dhawan SS, Sheikh A, Douglas JS, Veledar E, Mavromatis K et al. Usefulness of serum high-density lipoprotein cholesterol level as independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol 2009;103:902-906. 
  9. Sy R, Dans A, Eduardo F, Amarillo ML,Velandria F, for the FNRI HDL Study Group. The prevalence of dyslipidemia, diabetes, hypertension, stroke and angina pectoris in the Philippines. Phil J Int Med 2003;41:1-6. 
  10. Morales DD, Punzalan FER, Paz-Pacheco E, Sy RG, Duante CA. Metabolic syndrome in the Philippine general population: prevalence and risk for atherosclerotic cardiovascular disease and diabetes mellitus. National Nutrition and Health Survey (NNHES) 2003 group. 
  11. Serruys P, de Feyter P, Macaya C, et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention A Randomized Controlled Trial. JAMA 2002;287:3215- 3222. 
  12. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, Peterson KL, Reeves TJ, Williams DO, Winters WLJ. Guidelines January 2013 to June 2013 for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation 1988;78:486-502. 
  13. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; the Writing Group on behalf of the Joint ESC/ACCF/ AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Circulation 2012;126:2020-2035. 
  14. Hicks KA, HungHJ, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, Targum SL, Temple R; on behalf of the Standardized Data Collection for Cardiovascular Trials Initiative.Standardized Definitions for End Point Events in Cardiovascular Trials. Clinical Data Interchange Standards Consortium (CDISC), Health Level 7, Clinical TrialsTransformation Initiative (CTTI), industry, and the Food and Drug Administration (FDA). 
  15. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. JACC 2011;58:e44–122. 
  16. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C, for Treating to New Targets I. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301–1310. 
  17. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890–896. 
  18. Lu Q, Tian G, Zhang Y, Lu M, Lin X, Ma A. Low HDL predicts risk and PCI outcomes in the Han Chinese population. Atherosclerosis 2012 ;226(1):193-7. 
  19. Robins SJ,Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, et al for the VA-HIT Study Group. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary EventsVA-HIT: A Randomized Controlled Trial. JAMA 2001;285:1585-1591. 
  20. Barter PJ, Caulfield M, Eriksson M, Grundy M, Kastelein JJP, Komajda, M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, et al, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109 –2122. 
  21. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Nickens D, Koprowicz K, et al.Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N ENGL J MED 2011;365:2255-2267. 
  22. Takasu J, Budoff MJ, Katz R, Rivera JJ, O’Brien KD, Shavelle DM, Probstfield JL, O’Leary, MD D,Nasir K. Relationship between Common Carotid Intima-Media Thickness and Thoracic Aortic Calcification: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2010;209:142-146. 
  23. Libby P. Managing the risk of atherosclerosis: the role of high densitylipoprotein. Am J Cardiol 2001;88(suppl):3N–8N. 24. SoRelle R. ATP III calls for more intensive low-density lipoprotein lowering in target groups. Circulation 2002;106(suppl):e9068.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.